Tillkännagivande • Jun 05
ADBiotech Co., Ltd. announced that it has received KRW 13.261700256 billion in funding On June 4, 2026, the ADBiotech Co., Ltd. closed the transaction and amended the term of transaction, issued 7,270,669 common shares at an issue price of KRW 1,824 for the proceeds of KRW 13,261,700,256. Transaction involves participation of BK Partners Fund No. 1 for 5,987,774 shares and Ahn Byeong-hwa for 1,282,895 shares. Tillkännagivande • May 29
ADBiotech Co., Ltd. announced that it expects to receive KRW 3 billion in funding ADBiotech Co., Ltd. has announced a private placement of Series 10 Unregistered Interest Unsecured Private Convertible Bonds of the company to raise gross proceeds of KRW 3,000,000,000 on May 28, 2026. The transaction involves the new investor participation of BK Partners Fund No. 1 for KRW 3,000,000,000. The bonds are 100% convertible into 1,120,238 common shares of the company at a conversion price value of KRW 2,678 and carry interest rate of 0% and maturity interest rate of 3%. The conversion billing period starts from June 5, 2027 to May 5, 2031.The transaction has been approved by the board of directors of the company. The bonds have a maturity date of June 5, 2031. The transaction is expected to close on June 5, 2026. Tillkännagivande • Mar 17
ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026 ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:00 Tokyo Standard Time. Location: conference room, 39, geodudanji 1-gil, dongnae-myeon, gangwon-do, chuncheon South Korea New Risk • Mar 12
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 28% per year over the past 5 years. Shareholders have been substantially diluted in the past year (115% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩37.8b market cap, or US$25.5m). Tillkännagivande • Nov 16
ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million. ADBiotech Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.998208 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 296,208
Price\Range: KRW 3376
Transaction Features: Subsequent Direct Listing Tillkännagivande • Oct 28
ADBiotech Co., Ltd. announced that it expects to receive KRW 16.569996684 billion in funding ADBiotech Co., Ltd. announced a private placement to issue 6,152,988 shares at an issue price of KRW 2,693 per share for gross proceeds of KRW 16,569,996,684 on October 27, 2025. The transaction will include participation from new investor BK Partners Investment Fund 1 3,107,259 shares and BK Partners Investment Fund 2 3,045,729 shares. The transaction has been approved by shareholders, restricted to a hold period and expected to close on December 17, 2025. Tillkännagivande • Oct 21
ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million. ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.99846 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 346,140
Price\Range: KRW 2889
Transaction Features: Subsequent Direct Listing New Risk • Jul 25
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩35.5b market cap, or US$25.8m). Tillkännagivande • Jun 10
ADBiotech Co., Ltd. announced that it expects to receive KRW 8.285 billion in funding ADBiotech Co., Ltd. announces a private placement to issue 5,000,000 Common Shares at a price of KRW 1,657 for gross proceeds of KRW 8,285,000,000 on June 9, 2025. Expected closing date of the offering is October 31, 2025. New Risk • Jun 09
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 19% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩28.2b market cap, or US$20.9m). New Risk • May 30
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩4.3b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩4.3b free cash flow). Earnings have declined by 19% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10.0% average weekly change). Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩21.0b market cap, or US$15.2m). New Risk • Apr 26
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 24% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 19% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (24% increase in shares outstanding). Market cap is less than US$100m (₩19.8b market cap, or US$13.8m). Reported Earnings • Mar 26
Full year 2024 earnings released: ₩870 loss per share (vs ₩313 loss in FY 2023) Full year 2024 results: ₩870 loss per share (further deteriorated from ₩313 loss in FY 2023). Revenue: ₩11.1b (up 6.3% from FY 2023). Net loss: ₩7.95b (loss widened 178% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 49% per year whereas the company’s share price has fallen by 44% per year. New Risk • Mar 21
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₩13.0b (US$8.92m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 9.9% per year over the past 5 years. Market cap is less than US$10m (₩13.0b market cap, or US$8.92m). Tillkännagivande • Mar 18
ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2025 ADBiotech Co., Ltd., Annual General Meeting, Mar 31, 2025, at 14:00 Tokyo Standard Time. Location: conference room, 39, geodudanji 1-gil, dongnae-myeon, gangwon-do, chuncheon South Korea New Risk • Feb 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (₩22.4b market cap, or US$15.5m). Tillkännagivande • Dec 26
ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 8.000002 billion. ADBiotech Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 8.000002 billion.
Security Name: Common Stocks
Security Type: Common Stock
Securities Offered: 4,026,171
Price\Range: KRW 1987 New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩24.9b market cap, or US$17.3m). New Risk • Nov 28
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩171m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩171m free cash flow). Earnings have declined by 9.9% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Market cap is less than US$100m (₩25.1b market cap, or US$18.0m). New Risk • Sep 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (13% average weekly change). Minor Risk Market cap is less than US$100m (₩39.1b market cap, or US$29.4m). New Risk • Jun 03
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩30.1b market cap, or US$21.8m). Reported Earnings • Mar 22
Full year 2023 earnings released: ₩313 loss per share (vs ₩297 profit in FY 2022) Full year 2023 results: ₩313 loss per share (down from ₩297 profit in FY 2022). Revenue: ₩10.5b (down 1.5% from FY 2022). Net loss: ₩2.86b (down 206% from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 113% per year but the company’s share price has fallen by 25% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Dec 20
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to ₩4,060, the stock trades at a trailing P/E ratio of 10.7x. Average trailing P/E is 22x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 48% over the past three years. Valuation Update With 7 Day Price Move • Dec 04
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to ₩3,320, the stock trades at a trailing P/E ratio of 8.8x. Average trailing P/E is 21x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 49% over the past three years. New Risk • Dec 04
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (12% average weekly change). High level of non-cash earnings (31% accrual ratio). Minor Risk Market cap is less than US$100m (₩32.7b market cap, or US$25.1m). Valuation Update With 7 Day Price Move • Nov 20
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₩3,645, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 49% over the past three years. Reported Earnings • Nov 19
Third quarter 2023 earnings released: ₩104 loss per share (vs ₩29.00 loss in 3Q 2022) Third quarter 2023 results: ₩104 loss per share (further deteriorated from ₩29.00 loss in 3Q 2022). Revenue: ₩2.76b (up 48% from 3Q 2022). Net loss: ₩947.1m (loss widened 258% from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 148% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩3,475, the stock trades at a trailing P/E ratio of 7.7x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 41% over the past three years. Valuation Update With 7 Day Price Move • Sep 13
Investor sentiment improves as stock rises 35% After last week's 35% share price gain to ₩4,910, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 17x in the Pharmaceuticals industry in South Korea. Total loss to shareholders of 20% over the past three years. Tillkännagivande • Jan 17
ADBiotech Co., Ltd. (KOSDAQ:A179530) agreed to acquire a 19.36% stake in Wiju Inc. for KRW 1.29 billion. ADBiotech Co., Ltd. (KOSDAQ:A179530) agreed to acquire a 19.36% stake in Wiju Inc. for KRW 1.29 billion on January 13, 2023. Under the terms ADBiotech Co., Ltd. acquired 2,578,252 shares comprising of 34,451 shares of common stock and 2,543,801 shares of preferred stock. Post completion, ADBiotech Co., Ltd will own 3,528,252 shares representing 28.07% stake. The board of ADBiotech Co., Ltd. passed resolution for the transaction on January 13, 2023 and the transaction is expected to complete on January 17, 2023. Tillkännagivande • May 05
ADBiotech Co., Ltd. announced that it has received KRW 4.5 billion in funding On May 3, 2021, ADBiotech Co., Ltd. (XKON:A179530) closed the transaction. Tillkännagivande • Apr 24
ADBiotech Co., Ltd. announced that it expects to receive KRW 4.5 billion in funding ADBiotech Co., Ltd. (XKON:A179530) announced a private placement to issue series 5 registered non-guaranteed private convertible bonds for KRW 4,500,000,000 on April 22, 2021. The transaction will include participation from A-Stone Project 1 Fund for 2,500,000,000, Magna VITA Fund for KRW 700,000,000, Focus Super Rich Hedge Fund 5 for KRW 400,000,000, and other investors. The bonds carry no coupon and yield, and will mature on May 3, 2024. The bonds are 100% convertible into 170,240 common shares of the company representing 6.64% stake at the conversion price of KRW 26,433 per share. The conversion period will start from May 3, 2022 and May 2, 2024. The transaction is expected to close on May 3, 2021. The transaction has been approved by the board of directors of the company. Tillkännagivande • Feb 27
ADBiotech Co., Ltd., Annual General Meeting, Mar 30, 2021 ADBiotech Co., Ltd., Annual General Meeting, Mar 30, 2021, at 10:00 Korea Standard Time. Is New 90 Day High Low • Jan 14
New 90-day high: ₩26,700 The company is up 48% from its price of ₩18,000 on 16 October 2020. The South Korean market is up 31% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 17% over the same period. Is New 90 Day High Low • Dec 09
New 90-day high: ₩22,950 The company is up 28% from its price of ₩17,950 on 10 September 2020. The South Korean market is up 13% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 6.0% over the same period. Is New 90 Day High Low • Nov 13
New 90-day high: ₩20,000 The company is up 32% from its price of ₩15,200 on 14 August 2020. The South Korean market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. Is New 90 Day High Low • Oct 19
New 90-day high: ₩19,950 The company is up 33% from its price of ₩15,000 on 21 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 4.0% over the same period. Is New 90 Day High Low • Sep 21
New 90-day high: ₩19,000 The company is up 16% from its price of ₩16,450 on 23 June 2020. The South Korean market is up 15% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Pharmaceuticals industry, which is up 32% over the same period. Tillkännagivande • Jul 18
ADBiotech Co., Ltd. announced that it has received KRW 3.0000065 billion in funding from SBI Investment Korea Co., Ltd. On July 9, 2020, ADBiotech Co., Ltd. (XKON:A179530) closed the transaction. Tillkännagivande • Jul 02
ADBiotech Co., Ltd. announced that it expects to receive KRW 1 billion in funding ADBiotech Co., Ltd. (XKON:A179530) announced a private placement to issue 4th series named non-guaranteed private equity bonds for KRW 1,000,000,000 on June 30, 2020. The transaction will include participation from new investor IDV-IP Fisheries Professional Fund No. 2. The bonds bears an interest of 3% per annum and will mature on July 09, 2025. The bonds are 100% convertible into 56,179 common shares of the company representing 2.42% stake at the conversion price of KRW 17,800 per share. The conversion period will start from July 10, 2021 and ends on July 08, 2025. The subscription date for bonds is June 30, 2020 and payment date is July 09, 2020. The transaction has been approved by the board of directors of the company. Tillkännagivande • Jun 30
ADBiotech Co., Ltd. announced that it expects to receive KRW 3.0000065 billion in funding from SBI Investment Korea Co., Ltd. ADBiotech Co., Ltd. (XKON:A179530) announced a private placement of 206,897 convertible preferred shares at a price of KRW 14,500 per share for gross proceeds of KRW 3,000,006,500 on June 29, 2020. The transaction will include participation from SBI-Growth Ladder Konex Vitalization Fund No.2, a fund managed by returning investor SBI Investment Korea Co., Ltd. (KOSDAQ:A019550). The conversion period is between July 10, 2020 and July 09, 2030. The preferred shares are convertible into 206,897 common shares. The shares are redeemable. The repayment period is between July 10, 2023 and July 09, 2030.The transaction has been approved by the board of directors. The payment date is July 9, 2020. 